NIH SBIR/STTR Omnibus Solicitation

NIH SBIR/STTR Omnibus Solicitation

Overview in plain English

The NIH SBIR/STTR parent announcements are the main investigator-initiated route for U.S. small businesses developing biomedical, public-health, diagnostic, device, therapeutic, or related research products. They are not one undifferentiated grant with one universal award ceiling. The current group includes separate notices for SBIR, STTR, and a later-stage SBIR Phase IIB mechanism, each with its own activity codes and eligibility details.

The 2026–2027 parent notices are open, so this is a live listing rather than a historical archive. NIH posted PA-27-100 and PA-27-102 on May 28, 2026, and applications could first be submitted August 5, 2026. The first standard receipt date, September 5, 2026, has passed. NIH’s standard dates are September 5, January 5, and April 5; dates falling on weekends or Federal holidays move to the next business day. The next standard date is January 5, 2027, followed by April 5, 2027. Applications are due by 5:00 PM in the applicant organization’s local time, and the notices state that late applications will not be accepted. Leave time for electronic validation and any required correction before the applicable receipt date.

The official NIH SEED funding page lists four related parent notices: PA-27-100 for SBIR Phase I and Phase II pathways, PA-27-102 for STTR Phase I and Phase II pathways, PA-27-101 for the SBIR Phase IIB Strategic Breakthrough Award, and PAR-27-098 for the Commercialization Readiness Pilot. This page focuses on PA-27-100 and PA-27-102, because those are the broad entry points that most applicants mean when they search for the NIH SBIR/STTR omnibus solicitation.

At-a-glance summary

What this gives you and what it does not

You are applying for a structured, federal program designed to fund research and development needed to establish technical feasibility and advance a commercial product. It is not a guarantee of funding, a guaranteed purchase agreement, or a program for open-ended grants. NIH funding does not buy your company; it supports specific R&D activities and expects measurable progress.

Use this if your project has this shape:

• A technical idea with clear potential users or a problem statement.
• A path from prototype, assay, or platform to clinical/translational evidence.
• A timeline that can deliver objective milestones and outcomes.

Avoid this if your project is purely exploratory with no credible path to execution, or if you are not ready to meet federal-level compliance and reporting expectations.

What changed for the current cycle

The current parent notices replace the older PA-24 announcements. PA-27-100 covers SBIR Phase I and Phase II, including Direct to Phase II and Fast-Track options for NIH. PA-27-102 covers STTR Phase I and Phase II, including NIH Direct to Phase II and Fast-Track options. PA-27-101 is the separate Phase IIB Strategic Breakthrough Award and should not be used as a general replacement for a Phase I or Phase II application.

The notices were posted May 28, 2026, with an earliest submission date of August 5, 2026. Their standard receipt dates are September 5, 2026, January 5, 2027, and April 5, 2027. The September date has passed, leaving January 5 and April 5 as the remaining standard dates in these notices. Both parent notices expire April 6, 2027. Dates falling on weekends or Federal holidays move to the next business day, and late applications are not accepted.

Choosing SBIR or STTR

Choose PA-27-100, the parent SBIR notice, when the small business can carry out the required majority of the research or analytical effort and the project does not depend on the formal STTR structure. Under the current SBIR notice, the small business normally performs at least two-thirds of the Phase I research effort and at least one-half of the Phase II effort. The PD/PI’s primary employment must be with the small business at the time of award and during the proposed project, subject to the limited deviations described in the notice.

Choose PA-27-102, the parent STTR notice, when the project depends on a formal collaboration with a qualifying nonprofit research institution, such as a university. The award still goes to the small business. In both Phase I and Phase II, at least 40% of the research or analytical effort must be performed by the small business and at least 30% by the single partnering research institution. The remaining work can be allocated as allowed by the notice and application instructions. An STTR PD/PI may be primarily employed by either the small business or the nonprofit research partner.

Both notices mark clinical trials as optional, but that label does not mean every participating Institute or Center accepts every clinical-trial proposal. Check the component-specific restrictions in Section I of the selected notice. A clinical-trial application must include the required human-subjects and clinical-trial information and the regulatory plan described in the notice.

Amount and project period

There is no single omnibus award amount that applies to every applicant. PA-27-100 and PA-27-102 state that total support normally may not exceed current SBA budgetary guidelines, while NIH component tables set higher topic-specific amounts. Current examples include Phase I budgets of $400,000 or $700,000 and Phase II budgets of $2.5 million or $3 million, depending on the participating NIH component. Other components list the SBA guideline instead of a fixed amount. Approved waiver topics may permit higher support; CDC and FDA components under PA-27-100 normally follow current SBA guidelines. Confirm the table and topic-specific instructions for the component you target, contact program staff before requesting more than the guideline, and propose only a reasonable budget tied to the work. The number of awards depends on appropriations and the merit of applications received.

The budget must be reasonable for the proposed work, not simply the largest amount visible in the table. Tie personnel, subcontracting, equipment, testing, regulatory work, and other costs to specific aims and milestones. Contact the relevant component before submitting a budget above the normal SBA guideline or before relying on a waiver.

The current SBIR notice says award periods normally may not exceed six months for Phase I and two years for Phase II. The current STTR notice says Phase I normally may not exceed one year and Phase II two years. The proposed period should still match the actual research plan and the stage of the product.

Why this matters for founders and teams

The opportunity is one of the few pathways where a biomedical small business can get federal support without surrendering equity. Teams use it when:

• Venture funding is not yet available enough to complete early science.
• Internal budget is insufficient for full proof-of-concept work.
• The science has clear translational or commercialization potential.

Because this process is rules-heavy, disciplined teams often get the largest advantage over equally technical competitors. Success usually depends less on “idea quality” alone and more on execution quality: clear scope, realistic milestones, and a proposal format that matches NIH expectations.

Who this opportunity is for

This route is most suitable when you can answer all of these with confidence:

• Do we have a credible technical problem and a concrete userspace in healthcare, diagnostics, devices, therapeutics, digital health, or related biomedical R&D?
• Can we define milestones for a near-term review period that a panel can verify?
• Are we willing and able to provide compliant registration and submission artifacts?

It is generally good fit for:

• For-profit U.S. small businesses.
• Teams led by founders willing to run NIH-style applications and updates.
• Ideas that benefit from NIH review standards and network alignment with NIH Institutes and Centers.

It is generally poor fit for:

• Teams seeking pure grant-style funding with no commercialization path.
• Companies that cannot commit to the application timeline or documentation standards.
• Firms that cannot distinguish what is required by a parent NOFO versus a topic-specific NOFO.

Eligibility and program basics (the parts people often misread)

1) Small business requirements are strict and mechanical

The current parent notices say that only U.S. small business concerns can submit. The concern must be organized for profit, have a place of business in the United States, operate primarily in the United States or make a significant contribution to the U.S. economy, and have no more than 500 employees including affiliates. Teams should validate:

• Eligible ownership and control under the notice and SBA rules.
• Employee and affiliate counts.
• Whether the legal structure includes venture-capital, hedge-fund, or private-equity ownership that changes SBIR eligibility.
• Whether the company’s prior-award performance benchmarks affect a new Phase I, Fast-Track, or Direct to Phase II application.

The current notices also apply SBA/HHS performance benchmarks. These affect companies above specified prior-award thresholds, not every small business: transition-rate rules apply to firms with more than 20 Phase I awards in the relevant five-fiscal-year period, and commercialization benchmarks apply at specified Phase II award counts. A separate HHS-wide policy caps each small business concern, including affiliates, at nine new and resubmission Phase I, Fast-Track, and Direct to Phase II applications or contract proposals per fiscal year across SBIR and STTR. Ownership rules also differ: PA-27-100 allows certain concerns majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms, subject to its conditions; PA-27-102 excludes concerns more than 50% owned by those investor groups. Check the notice and your company’s award history before choosing a mechanism.

2) SBIR and STTR differ in partner rules

A critical difference is how research partnerships with nonprofit institutions are treated. SBIR allows research partnerships, but the small business normally performs at least two-thirds of Phase I and one-half of Phase II research effort, and at least one PD/PI must be primarily employed by the small business. STTR requires one qualifying nonprofit research institution partner; at least 40% of the work must be performed by the small business and at least 30% by that partner. An STTR PD/PI may be primarily employed by either organization but must have a formal appointment or commitment to the applicant business. Read the active NOFO before relying on an old proposal template.

3) Clinical trial status and special handling vary by solicitation

Some solicitation documents require specific clinical-trial handling and some restrict it. That is NOFO-level logic, not a universal rule across the entire program. Always check:

• Funding opportunity text, especially Section IV (Application and Submission Information).
• Related notices in the NIH Guide.
• The relevant Notices section in your assigned Institute/Center interest page.

If you force an assumption here (for example, that a project is automatically allowed for clinical work), you risk a avoidable rejection point.

How to decide whether to apply (a practical filter)

Before you even start writing, score your readiness from 0–3 in each row:

1. Problem clarity
2. Technical risk management
3. Regulatory and compliance capacity
4. Submission timeline control
5. Commercial realism
6. Registration readiness

If you cannot score at least three items at 2+ out of 3, pause and prepare first. NIH does not reject only weak science; it often rejects weak readiness.

A strong readiness profile looks like this:

• Your problem is narrow enough to be measurable.
• Your team can explain exactly what “success” looks like by proposal period.
• Your registration stack (SAM, eRA Commons, Grants.gov, SBA registrations) is already in progress or complete.
• You know which nofo type you are applying to before proposal writing starts.

The route decision: parent announcement vs specific NOFO

NIH’s own framework separates these clearly:

Parent announcements (omnibus)

These are investigator-initiated and broader in topic framing. You use them when your idea is not tied to a tightly defined topic and you can still map your approach to NIH priorities.

Specific opportunities (RFA/PAS/PAS-linked)

These are narrow, often topic-specific, and can include stricter scope constraints, review expectations, and budgets.

How to choose

• Use the parent lane if your innovation is broadly applicable and you need the flexibility.
• Use specific NOFO lane if you have a strong match to a clear announced theme and want targeted competition.

Choosing wrong is one of the most expensive errors because you burn time on the wrong instructions.

Confirm active status before you write a line of proposal prose

For the current cycle:

1. Confirm the NOFO number and title from SEED and/or Grants.gov.
2. Pull the NIH NOFO package and read the key sections.
3. Confirm whether the mechanism is SBIR or STTR and what phase is open (Phase I, Fast Track, direct Phase II, etc.).

The current parent notices are published and have two standard receipt dates remaining in this cycle. Do not write against the retired PA-24 announcements; use PA-27-100 or PA-27-102 and the current SF-424 (R&R) SBIR/STTR Application Guide. The NOFO’s Section IV supplies program-specific application instructions and takes precedence where it differs from the guide.

Step-by-step application process (practical)

Step 1: Registration and system readiness (must be done early)

NIH requires the organization to complete and maintain registrations before submitting an application. The current notices identify these systems and require all organizational registrations to be complete before submission:

• SAM.gov registration.
• eRA Commons.
• Grants.gov credentials and organization access.
• A consistent UEI across the organization’s SAM and eRA Commons profiles.
• An eRA Commons account for each PD/PI, with that person’s Commons profile linked to a valid ORCID iD.

NIH says the complete registration process can take six weeks or more. Complete and maintain the required registrations in SAM.gov, eRA Commons, Grants.gov, and the SBA Company Registry well before the January 5, 2027 receipt date. Use the same UEI across registrations and on the application. The current notice requires SBA Company Registry registration and directs applicants to attach proof of registration to the application package. You need a UEI to register with SBA, but SBA Company Registry registration is not a prerequisite to starting SAM, Grants.gov, or eRA Commons registration. Confirm account roles, make sure all required registrations are complete before submission, and leave time for electronic validation. Starting registrations late does not qualify as a reason for a late filing.

Step 2: Select the right instruction set

Use the current NIH Application Guide and the Version I SBIR/STTR instructions linked in the active application package. Read Section IV of the selected NOFO for program-specific requirements; follow those instructions where they differ from the general guide. Check related NIH policy notices as well, since they can update requirements. Do not reuse forms or attachments from a retired announcement without checking the current package.

Step 3: Build with the right submission path

NIH identifies three electronic submission routes:

• NIH ASSIST.
• An institutional system-to-system solution.
• Grants.gov Workspace.

Submit electronically through one of the routes allowed in the NOFO: NIH ASSIST, an institutional system-to-system solution, or Grants.gov Workspace. Paper applications are not accepted. After submission, track the application in eRA Commons, correct processing errors by the due date, and view the assembled application. Confirm that the final assembled application is complete and visible for review.

Step 4: Draft around reviewability, not verbosity

Your proposal should be reviewable by a busy reviewer:

• Clear problem statement with specific clinical or user pain.
• Defined aims and milestones per phase.
• Evidence plan that states what exists, what is missing, and how missing evidence will be generated.
• Commercial rationale for the next step after NIH funding.
• Work-plan split that respects SBIR/STTR rules.

Step 5: Internal technical + compliance review

Do not skip this. Build a two-pass review:

• Technical pass: does the plan solve the stated problem?
• Compliance pass: does the packet match required forms, checklists, and NOFO-specific instructions?

Step 6: Submit and verify

Submit through the official system, capture the receipt, and track your status via NIH/ERA channels.

Step 7: After submission

Use the submitted materials as a living package:

• Respond quickly to administrative or scientific follow-up requests.
• Keep clean versioning of attachments and evidence.
• Maintain a single person accountable for status tracking and communications.

Step 8: Prepare for Just-In-Time review

An application may receive a favorable review without becoming an award automatically. If NIH, CDC, or FDA considers it for funding, respond to Just-In-Time requests through the specified agency system. Both PA-27-100 and PA-27-102 require applicants under consideration for award to provide the SBA Required Disclosures of Foreign Affiliations or Relationships to Foreign Countries form for owners and covered individuals during Just-in-Time review. The form covers funded and unfunded relationships. Both notices also describe security-related grounds on which an award may be denied. Gather accurate ownership, affiliation, and relationship information early, route the disclosure through the authorized business official, and answer agency requests by their stated date. This disclosure is a post-submission award-stage requirement, not an attachment to add to every initial application.

Required materials and planning checklist

Below is a practical baseline checklist based on official NIH guidance and common submission mechanics.

• Opportunity package: NOFO, NIH Application Guide references, Section IV and FAQ sections.
• Title page and abstract that map directly to the scope.
• Project narrative that separates scientific objectives and commercialization logic.
• Budget and budget justification tied to tasks.
• Team and roles, including PI and subcontracting relationships.
• Regulatory readiness: if human subjects or clinical work is involved, include complete relevant documents.
• A commercialization plan for Phase II and Fast-Track applications; the current notices do not allow one for Phase I.
• No Data Management and Sharing Plan for these parent NOFOs, because the notices state that it is not applicable.
• Human-subjects and clinical-trial records, plus the regulatory plan, when the project requires them.
• STTR partner roles and work allocation when applying to PA-27-102, including the required single nonprofit research institution or eligible FFRDC partner.
• Proof of SBA Company Registry registration in the application package, and, only when applicable, the signed SBIR VCOC Certification for a business majority-owned by multiple venture capital operating companies, hedge funds, or private equity firms.
• If the application is under consideration for an award, the SBA Required Disclosures of Foreign Affiliations or Relationships to Foreign Countries form during the Just-In-Time process for owners and other covered individuals; applicants also need to satisfy any applicable security review.

For NIH small-business applicants, this check is usually where applications are won or lost. If your proposal “sounds impressive” but is missing a required section, it fails to score well even with strong science.

Readiness to apply: common mistakes to avoid

1. Submitting without registrations complete.
2. Writing against the retired PA-24 announcement or the wrong current mechanism.
3. Treating STTR and SBIR partner expectations as identical.
4. Assuming all NIH NOFOs accept the same clinical trial posture.
5. Missing the shifted deadline rule (weekend/holiday moved to next business day).
6. Adding a Phase I commercialization plan, Data Management and Sharing Plan, or prohibited Phase I appendix.
7. Overloading the proposal with broad science and under-defining milestones.
8. Confusing eligibility with “how much I wish” instead of checking SBA and program rules directly.

The recurring pattern is that applicants lose points on structure and compliance, not only on raw science.

At-a-glance readiness matrix

Use this as a pre-submission filter in the final 72 hours:

• I confirmed a live NOFO and its exact mechanism.
• My team has verified SBIR/STTR mechanism eligibility under SBA and NIH rules.
• Our planned HHS SBIR/STTR new and resubmission Phase I, Fast-Track, and Direct to Phase II submissions stay within the nine-application annual cap.
• STTR collaborators are in place where required and documented.
• Registrations are complete and active (SAM.gov, eRA Commons, Grants.gov, and the SBA Company Registry); proof of SBA Company Registry registration is included in the application package.
• PI role, workshare, and budget align with the active NOFO.
• I reviewed NIH Application Guide and the applicable SBIR/STTR instruction set.
• I completed at least one compliance-focused pre-review.
• I tested submission path and validated confirmation behavior.
• I have a response owner for review questions and an escalation path for system issues.

Timeline model

For the next standard receipt date, January 5, 2027, use a realistic schedule:

• Weeks 1–2: Confirm the exact opportunity and map scope.
• Weeks 3–4: Register/verify systems, define milestones, write first pass.
• Weeks 5–6: Budget, compliance, and draft attachments.
• Weeks 7–8: Internal reviews and revisions.
• Weeks 9–10: Final form validation and pre-submission checks.
• Week 11: Submit early (ideally at least one business day before official date).

For specific component requirements, compress this timeline and build contingency time for external science review. NIH encourages early submission because the applicant must have time to correct errors before the deadline.

FAQ

Is the current page historical?

No. NIH’s current parent notices PA-27-100 and PA-27-102 remain open for the 2026–2027 cycle. The September 5, 2026 standard receipt date moved to September 8 because September 5 fell on a Saturday; that date has passed. January 5, 2027 is next, followed by April 5, 2027. Both notices expire April 6, 2027. The NIH SEED parent-announcement page lists these notices as current. Confirm the live notice package and any related policy updates before submitting.

What should I do before the next receipt date?

Use the time before January 5, 2027 to complete registrations, clean proposal artifacts, and align your team with the PI/partner structure and compliance checklist. The announcement is already open; check the notice for the receipt-date rules and leave time to correct system errors.

Is this route only for NIH-funded technologies?

No. The route is generally for early-stage technologies with strong scientific and commercialization logic. Prior funding may help, but it is not the only path.

Can STTR and SBIR both use the same submission system?

Yes, both route through NIH systems, but the instructions differ by mechanism. The active NOFO text is what determines PI roles and partner expectations.

Can I still contact NIH before applying?

Yes, use the official support pathways on NIH/SEED pages to ask pre-application or mechanism questions and to confirm fit. The current notices encourage applicants to contact the appropriate NIH component before submitting.

How often do deadlines move?

NIH lists September 5, January 5, and April 5 as standard dates, and dates that fall on weekends or Federal holidays move to the next business day. The September 5, 2026 receipt date therefore moved to September 8 and has passed. The notices do not accept late applications. The next standard date is January 5, 2027; April 5, 2027 is the final standard date listed before expiration.

What to do next

If you are ready now

• Subscribe to official updates from SEED and monitor the current Grants.gov notice package.
• Define your project in one sentence: problem, user, milestone, and proof point.
• Keep your registrations current and test each submission system before the January 5, 2027 receipt date.

If your project is not a fit yet

• Tighten the PI role and ownership model first.
• Clarify partner expectations for STTR.
• Add missing bench-to-human evidence milestones.
• Reassess against the current PA-27-100 or PA-27-102 notice.

Official links you should bookmark now

• NIH SBIR/STTR funding opportunities (NIH SEED)
• PA-27-100 current SBIR parent notice
• PA-27-102 current STTR parent notice
• How to apply (NIH SEED)
• Prepare your application (NIH SEED)
• NIH Application Guide
• NIH SBIR/STTR instruction pages are linked from NOFO text and the NIH Application Guide; use those links plus Section IV of your active NOFO for the official filing requirements
• NIH Guide for Grants & Contracts
• NIH parent announcements and specific small-business opportunities
• NIH HHS Small Business Program contact list and considerations
• Eligibility criteria and ownership considerations (NIH SEED)

Final decision guide

At a glance, this opportunity is worth your time when three conditions are true:

1. You have a defined biomedical problem and a measurable development path.
2. Your ownership and partnership structure can pass SBA/NIH rules for the mechanism you need.
3. You are ready to execute a strict federal submission process without last-minute scrambling.

If one condition is still weak, use the time before the January 5, 2027 receipt date to address it, or plan for April 5, 2027 if the work needs more time. NIH requires strict conformance to the application guide and notice-specific instructions; confirm all dates, component participation, and policies against the live notice package before filing.